SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

Search

Valneva SE

Open

2.73 -14.69

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.65

Max

3.21

Schlüsselkennzahlen

By Trading Economics

Einkommen

-28M

-37M

Verkäufe

7.1M

53M

EPS

-0.25

Gewinnspanne

-69.865

Angestellte

713

EBITDA

-19M

-26M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+76.47% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-64M

513M

Vorheriger Eröffnungskurs

17.42

Vorheriger Schlusskurs

2.73

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Valneva SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Nov. 2024, 10:28 UTC

Wichtige Markttreiber

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3. Sept. 2024, 10:28 UTC

Ergebnisse

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15. Nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3. Sept. 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Peer-Vergleich

Kursveränderung

Valneva SE Prognose

Kursziel

By TipRanks

76.47% Vorteil

12-Monats-Prognose

Durchschnitt 5.7 EUR  76.47%

Hoch 8.1 EUR

Tief 3.3 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Valneva SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

3.17 / 3.33Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.